tbuckley/cabot-search huggingface dataset:
Part 3: Adult Basic and Advanced Life Support: 2020 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care
Authors: Ashish R. Panchal, Jason A. Bartos, José G. Cabañas, Michael W. Donnino, Ian R. Drennan, Karen G. Hirsch, Peter J. Kudenchuk, Michael C. Kurz, Eric J. Lavonas, Peter T. Morley, Brian J. O’Neil, Mary Ann Peberdy, Jon C. Rittenberger, Amber J. Rodriguez, Kelly N. Sawyer, Katherine M. Berg, Julie Arafeh, Justin L. Benoit, Maureen Chase, Antonio Fernandez, Edison Ferreira de Paiva, Bryan L. Fischberg, Gustavo E. Flores, Peter Fromm, Raul Gazmuri, Blayke Courtney Gibson, Theresa Hoadley, Cindy H. Hsu, Mahmoud Issa, Adam Kessler, Mark S. Link, David J. Magid, Keith Marrill, Tonia Nicholson, Joseph P. Ornato, Garrett Pacheco, Michael Parr, Rahul Pawar, James Jaxton, Sarah M. Perman, James Pribble, Derek Robinett, Daniel Rolston, Comilla Sasson, Sree Veena Satyapriya, Travis Sharkey, Jasmeet Soar, Deb Torman, Benjamin Von Schweinitz, Anezi Uzendu, Carolyn M. Zelop, David J. Magid
Journal: Circulation (2020)
Impact and treatment of diabetes (Type I and II) on prognosis in acute coronary syndromes: Results from the global registry of acute coronary events Joel M. Gore, Frederick A. Spencer, Michel Marre, Robet J. Goldberg, Werner Klein, Rachel S. Kasper, Andrzej Budaj, Tomek Mazurek, Ph Gabriel Steg, for the GRACE Investigators. University of Massachusetts Medical School, Worcester, MA, H�pital Bichat, Paris, France
Journal: Journal of the American College of Cardiology (2001)
JAMA 75 YEARS AGO
Journal: JAMA (1979)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Dietary Fructose Promotes Prostate Cancer Growth
Authors: Daniela V. Carreño, Néstor B. Corro, Javier F. Cerda-Infante, Carolina E. Echeverría, Catalina A. Asencio-Barría, Verónica A. Torres-Estay, Gonzalo A. Mayorga-Weber, Pablo A. Rojas, Loreto P. Véliz, Pedro A. Cisternas, Viviana P. Montecinos, Ignacio F. San Francisco, Manuel A. Varas-Godoy, Paula C. Sotomayor, Maite A. Castro, Francisco J. Nualart, Nibaldo C. Inestrosa, Alejandro S. Godoy
Journal: Cancer Research (2021)

Abstract Clinical localization of primary tumors and sites of metastasis by PET is based on the enhanced cellular uptake of 2-deoxy-2-[18F]-fluoro-D-glucose (FDG). In prostate cancer, however, PET-FDG imaging has shown limited clinical applicability, suggesting that prostate cancer cells may utilize hexoses other than glucose, such as fructose, as the preferred energy source. Our previous studies suggested that prostate cancer cells overexpress fructose transporters, but not glucose transporters, compared with benign cells. Here, we focused on validating the functional expression of fructose transporters and determining whether fructose can modulate the biology of prostate cancer cells in vitro and in vivo. Fructose transporters, Glut5 and Glut9, were significantly upregulated in clinical specimens of prostate cancer when compared with their benign counterparts. Fructose levels in the serum of patients with prostate cancer were significantly higher than healthy subjects. Functional expression of fructose transporters was confirmed in prostate cancer cell lines. A detailed kinetic characterization indicated that Glut5 represents the main functional contributor in mediating fructose transport in prostate cancer cells. Fructose stimulated proliferation and invasion of prostate cancer cells in vitro. In addition, dietary fructose increased the growth of prostate cancer cell line–derived xenograft tumors and promoted prostate cancer cell proliferation in patient-derived xenografts. Gene set enrichment analysis confirmed that fructose stimulation enriched for proliferation-related pathways in prostate cancer cells. These results demonstrate that fructose promotes prostate cancer cell growth and aggressiveness in vitro and in vivo and may represent an alternative energy source for prostate cancer cells. Significance: This study identifies increased expression of fructose transporters in prostate cancer and demonstrates a role for fructose as a key metabolic substrate supporting prostate cancer cells, revealing potential therapeutic targets and biomarkers.
Serum total cholesterol, high-density lipoprotein, and prognosis in patients with chronic heart failure Mathias Rauchhaus, Wolfram Doehner, Constantinos H. Davos, Rakesh Sharma, Aidan Bolger, Heike Gabriel, Michael Kemp, Andrew J. S. Coats, Stefan D. Anker. NHLI, Clinical Cardiology, London, United Kingdom, Martin-Luther-Universit�t Halle-Wittenberg, Klinik f�r Innere Medizin III, Halle/Saale, Germany
Journal: Journal of the American College of Cardiology (2001)
Gentiopicroside targets PAQR3 to activate the PI3K/AKT signaling pathway and ameliorate disordered glucose and lipid metabolism
Authors: Haiming Xiao, Xiaohong Sun, Zeyuan Lin, Yan Yang, Meng Zhang, Zhanchi Xu, Peiqing Liu, Zhongqiu Liu, Heqing Huang
Journal: Acta Pharmaceutica Sinica B (2022)

The obstruction of post-insulin receptor signaling is the main mechanism of insulin-resistant diabetes. Progestin and adipoQ receptor 3 (PAQR3), a key regulator of inflammation and metabolism, can negatively regulate the PI3K/AKT signaling pathway. Here, we report that gentiopicroside (GPS), the main bioactive secoiridoid glycoside of Gentiana manshurica Kitagawa, decreased lipid synthesis and increased glucose utilization in palmitic acid (PA) treated HepG2 cells. Additionally, GPS improved glycolipid metabolism in streptozotocin (STZ) treated high-fat diet (HFD)-induced diabetic mice. Our findings revealed that GPS promoted the activation of the PI3K/AKT axis by facilitating DNA-binding protein 2 (DDB2)-mediated PAQR3 ubiquitinated degradation. Moreover, results of surface plasmon resonance (SPR), microscale thermophoresis (MST) and thermal shift assay (TSA) indicated that GPS directly binds to PAQR3. Results of molecular docking and cellular thermal shift assay (CETSA) revealed that GPS directly bound to the amino acids of the PAQR3 NH2-terminus including Leu40, Asp42, Glu69, Tyr125 and Ser129, and spatially inhibited the interaction between PAQR3 and the PI3K catalytic subunit (P110α) to restore the PI3K/AKT signaling pathway. In summary, our study identified GPS, which inhibits PAQR3 expression and directly targets PAQR3 to restore insulin signaling pathway, as a potential drug candidate for the treatment of diabetes.
Error in Article Information
Journal: JAMA Network Open (2022)

Francesco Menichetti, MD; Patrizia Popoli, MD; Maria Puopolo, MS; Stefania Spila Alegiani, MS; Giusy Tiseo, MD; Alessandro Bartoloni, MD; Giuseppe Vittorio De Socio, MD; Sauro Luchi, MD; Pierluigi Blanc, MD; Massimo Puoti, MD; Elena Toschi, MS; Marco Massari, MS; Lucia Palmisano, MS; Giuseppe Marano, MD; Margherita Chiamenti, MD; Laura Martinelli, MD; Silvia Franchi, MD; Carlo Pallotto, MD; Lorenzo Roberto Suardi, MD; Barbara Luciani Pasqua, MD; Marco Merli, MD; Plinio Fabiani, MD; Luca Bertolucci, MD; Beatrice Borchi, MD; Sara Modica, MD; Sara Moneta, MD; Giulia Marchetti, MD; Antonella d’Arminio Monforte, MD; Laura Stoppini, MD; Nadia Ferracchiato, MD; Stefania Piconi, MD; Claudio Fabbri, MD; Enrico Beccastrini, MD; Riccardo Saccardi, MD; Andrea Giacometti, MD; Sara Esperti, MD; Piera Pierotti, MD; Laura Bernini, MD; Claudia Bianco, MD; Sara Benedetti, MD; Alessandra Lanzi, MD; Paolo Bonfanti, MD; Marco Massari, MD; Spartaco Sani, MD; Annalisa Saracino, MD; Antonella Castagna, MD; Luigia Trabace, PhD; Maria Lanza, MD; Daniele Focosi, MD; Alessandro Mazzoni, MD; Mauro Pistello, MD; Marco Falcone, MD; TSUNAMI Study group; Roberto Palazzolo; Salvatore Casari; Alessandro Occhionero; Tiziana Grazzini; Dina Leonarda Silvestri; Mariacarla Iorio; Andrea Tosti; Daniela Francisci; Cecilia Becattini; Matteo Pirro; Mauro Marchesi; Sabrina Bastianelli; Sara Pierucci; Chiara Busti; Antonella Mencacci; Silvia Bozza; Barbara Camilloni; Valentina Annoni; Chiara Bellotto; Adriano Cioppi; Giorgia Querci; Giacomo Ciusa; Michela Tassara; Anna Danise; Silvia Chigiotti; Giovanna Morelli; Micaela Meini; Valentina Galfo; Simone Ferranti; Enrico Tagliaferri; Riccardo Iapoce; Chiara Barbieri; Arianna Forniti; Claudio Caroselli; Stefano Verdenelli; Fabio Monzani; Paola Mazzetti; Giovanna Moscato; Francesco Barchiesi; Mauro Andreotti; Fausto Baldanti; Andrea Binelli; Maria R Capobianchi; Roberto Da Cas; Daniela Di Sevo; Paola Fazi; Cinzia Gasparrini; Ilaria Ippoliti; Alessandra Mancino; Francesca Menniti Ippolito; Francesca Paoloni; Paola Ruggeri; Arianna Rughini; Emanuela Salvi; Valeria Sargentini; Maria P Trotta; Marco Vignetti
St. Isidore of Seville (c 560-636), medieval encyclopedist
Journal: JAMA (1968)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Mechanically Competent Chitosan‐Based Bioadhesive for Tendon‐to‐Bone Repair
Authors: Fei Fang, Roscoe T. H. Linstadt, Guy M. Genin, Kollbe Ahn, Stavros Thomopoulos
Journal: Advanced Healthcare Materials (2022)

Abstract Current suture‐based surgical techniques used to repair torn rotator cuff tendons do not result in mechanically competent tendon‐to‐bone attachments, leading to high postoperative failure rates. Although adhesives have been proposed to protect against sutures tearing through tendon during healing, no currently available adhesive meets the clinical needs of adhesive strength, biocompatibility, and promotion of healing. Here, a biocompatible, graded, 3,4‐dihydroxy phenyl chitosan (BGC) bioadhesive designed to meet these needs is presented. Although 3,4‐dihydroxy phenyl chitosan (DP‐chitosan) bioadhesives are biocompatible, their adhesion strength is low; soluble oxidants or cross‐linking agents can be added for higher bonding strength, but this sacrifices biocompatibility. These challenges are overcome by developing a periodate‐modified ion exchange resin‐bead filtration system that oxidizes catechol moieties to quinones and filters off the activating agent and resin. The resulting BGC bioadhesive exhibited sixfold higher strength compared to commercially available tissue adhesives, with strength in the range necessary to improve tendon‐to‐bone repair (≈1MPa, ≈20% of current suture repair strength). The bioadhesive is biocompatible and promoted tenogenesis; cells exposed to the bioadhesive demonstrated enhanced expression of collagen I and the tenogenic marker Scx. Results demonstrated that the bioadhesive has the potential to improve the strength of a tendon‐to‐bone repair and promote healing.
Miscellany.
Journal: JAMA (1899)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The office of decedent affairs
Authors: J. R. Carter
Journal: JAMA (1992)

<h3>To the Editor.</h3> —Haque et al<sup>1</sup>are to be congratulated for establishing a Decedent Affairs Office within their Department of Pathology. Admirable though their presentation was, the office they described as being unique most assuredly is not. A strikingly similar system, conceptually and practically, with virtually identical goals and objectives, was established at the University of Iowa Hospitals and Clinics in the early 1950s, at the University of Kansas Medical Center in 1960, at the University Hospitals of Cleveland and Case Western Reserve University in 1967, at the Arizona Health Sciences Center in 1971, at the M. S. Hershey Medical Center in 1971, and at the Hahnemann University Hospital in 1986. There may be others. Common to the execution of each of these programs was a truly unique feature, namely, the employment of licensed morticians and the creation of a Mortician's Office. The choice of morticians as the center
HYBRID CORONARY REVASCULARIZATION FOR THE TREATMENT OF CORONARY ARTERY DISEASE: A MULTICENTER OBSERVATIONAL STUDY
Authors: John D. Puskas, Deborah Ascheim, Michael Halkos, Emilia Bagiella, Joseph DeRose, Marissa Miller, Katherine Kirkwood, Johannes Bonatti, Vankeepuram Srinivas, Mark Vesely, Francis Sutter, Janine Lynch, Timothy Shapiro, Konstantinos Boudoulas, Juan Crestanello, Thomas Gehrig, Peter Smith, Michael Ragosta, Steven Hoff, David Zhao, Annetine Gelijns, Wilson Szeto, Giora Weisz, Michael Argenziano, William Matthai
Journal: Journal of the American College of Cardiology (2013)
Effect of dexamethasone as an analgesic adjuvant to multimodal pain treatment after total knee arthroplasty: randomised clinical trial
Authors: Kasper Smidt Gasbjerg, Daniel Hägi-Pedersen, Troels Haxholdt Lunn, Christina Cleveland Laursen, Majken Holmqvist, Louise Ørts Vinstrup, Mette Ammitzboell, Karina Jakobsen, Mette Skov Jensen, Marie Jøhnk Pallesen, Jens Bagger, Peter Lindholm, Niels Anker Pedersen, Henrik Morville Schrøder, Martin Lindberg-Larsen, Anders Kehlet Nørskov, Kasper Højgaard Thybo, Stig Brorson, Søren Overgaard, Janus Christian Jakobsen, Ole Mathiesen
Journal: BMJ (2022)

Abstract Objective To investigate the effects of one and two doses of intravenous dexamethasone in patients after total knee arthroplasty. Design Randomised, blinded, placebo controlled trial with follow-up at 90 days. Setting Five Danish hospitals, September 2018 to March 2020. Participants 485 adult participants undergoing total knee arthroplasty. Intervention A computer generated randomised sequence stratified for site was used to allocate participants to one of three groups: DX1 (dexamethasone (24 mg)+placebo); DX2 (dexamethasone (24 mg)+dexamethasone (24 mg)); or placebo (placebo+placebo). The intervention was given preoperatively and after 24 hours. Participants, investigators, and outcome assessors were blinded. All participants received paracetamol, ibuprofen, and local infiltration analgesia. Main outcome measures The primary outcome was total intravenous morphine consumption 0 to 48 hours postoperatively. Multiplicity adjusted threshold for statistical significance was P&lt;0.017 and minimal important difference was 10 mg morphine. Secondary outcomes included postoperative pain. Results 485 participants were randomised: 161 to DX1, 162 to DX2, and 162 to placebo. Data from 472 participants (97.3%) were included in the primary outcome analysis. The median (interquartile range) morphine consumptions at 0-48 hours were: DX1 37.9 mg (20.7 to 56.7); DX2 35.0 mg (20.6 to 52.0); and placebo 43.0 mg (28.7 to 64.0). Hodges-Lehmann median differences between groups were: −2.7 mg (98.3% confidence interval −9.3 to 3.7), P=0.30 between DX1 and DX2; 7.8 mg (0.7 to 14.7), P=0.008 between DX1 and placebo; and 10.7 mg (4.0 to 17.3), P&lt;0.001 between DX2 and placebo. Postoperative pain was reduced at 24 hours with one dose, and at 48 hours with two doses, of dexamethasone. Conclusion Two doses of dexamethasone reduced morphine consumption during 48 hours after total knee arthroplasty and reduced postoperative pain. Trial registration Clinicaltrials.gov NCT03506789 .
Generation coronavirus?
Authors: None The Lancet
Journal: The Lancet (2020)

The catastrophic elements that have perpetuated the COVID-19 pandemic—global interconnectedness, climate change due to human activity, vast economic inequality, and deep veins of antiscience—have resulted in more than 9 million infections and almost 500 000 deaths worldwide. Although children might be less susceptible to infection by severe acute respiratory syndrome coronavirus 2 and generally have better outcomes than adults, COVID-19 as a phenomenon weighs heavily on their health and wellbeing.
Drake, the many-sided physician
Authors: A. G. King
Journal: JAMA (1985)

<i>sylvis nuncius</i>was the motto chosen by Daniel Drake in 1828 for the<i>Western Journal of Medical and Physical Sciences</i>. Translatable as "Messenger From the Backwoods," it accurately describes the man himself. He made known to the world that Cincinnati was emerging from a frontier settlement into an important focus of agricultural, mercantile, and cultural development. Fully as important as the message was the messenger, a citizen as well as a great physician. In 1800 Cincinnati was a frontier village of 750 people depending for survival on Fort Washington and its garrison. The Treaty of Greenville, by which the Indians had agreed to withdraw beyond a line a little west of Cincinnati, was only five years old. The economic devastation following the American Revolution had sent people west to start a new life. Of these a few were restless adventurers who craved a continuation of the stirring events of only
Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma
Authors: Simona Serratì, Michele Guida, Roberta Di Fonte, Simona De Summa, Sabino Strippoli, Rosa Maria Iacobazzi, Alessandra Quarta, Ivana De Risi, Gabriella Guida, Angelo Paradiso, Letizia Porcelli, Amalia Azzariti
Journal: Molecular Cancer (2022)

Abstract Background The immunotherapy with immune checkpoints inhibitors (ICI) has changed the life expectancy in metastatic melanoma (MM) patients. Nevertheless, several patients do not respond hence, the identification and validation of novel biomarkers of response to ICI is of crucial importance. Circulating extracellular vesicles (EVs) such as PD-L1 + EV mediate resistance to anti-PD1, instead the role of PD1 + EV is not fully understood. Methods We isolated the circulating EVs from the plasma of an observational cohort study of 71 metastatic melanoma patients and correlated the amount of PD-L1 + EVs and PD1 + EVs with the response to ICI. The analysis was performed according to the origin of EVs from the tumor and the immune cells. Subsequently, we analysed the data in a validation cohort of 22 MM patients to assess the reliability of identified EV-based biomarkers. Additionally we assessed the involvement of PD1 + EVs in the seizure of nivolumab and in the perturbation of immune cells-mediated killing of melanoma spheroids. Results The level of PD-L1 + EVs released from melanoma and CD8 + T cells and that of PD1 + EVs irrespective of the cellular origin were higher in non-responders. The Kaplan-Meier curves indicated that higher levels of PD1+ EVs were significantly correlated with poorer progression-free survival (PFS) and overall survival (OS). Significant correlations were found for PD-L1 + EVs only when released from melanoma and T cells. The multivariate analysis showed that high level of PD1 + EVs, from T cells and B cells, and high level of PD-L1 + EVs from melanoma cells, are independent biomarkers of response. The reliability of PD-L1 + EVs from melanoma and PD1 + EVs from T cells in predicting PFS was confirmed in the validation cohort through the univariate Cox-hazard regression analysis. Moreover we discovered that the circulating EVs captured nivolumab and reduced the T cells trafficking and tumor spheroids killing. Conclusion Our study identified circulating PD1 + EVs as driver of resistance to anti-PD1, and highlighted that the analysis of single EV population by liquid biopsy is a promising tool to stratify MM patients for immunotherapy.